Adverse effect of intrapleural Corynebacterium parvum as adjuvant therapy in resected stage I and II non-small cell carcinoma of the lung. Ludwig Lung Cancer Study Group

J Thorac Cardiovasc Surg. 1985 Jun;89(6):842-7.


Intrapleural Corynebacterium parvum 7 mg or placebo was administered postoperatively as adjuvant therapy to patients with resected Stage I and II non-small cell lung cancer in a prospective, randomized, multicenter trial. A total of 475 patients were entered into this study between July, 1977, and February, 1979. Of this group, 405 can be evaluated, with an average follow-up time of 4.6 years. More side effects, especially fever and chest pain, were observed in patients receiving Corynebacterium parvum (p less than 0.001). An increase in fever was associated with a decrease in survival (p = 0.01). Life-threatening or fatal complications were not seen. Important prognostic factors are surgical stage (p less than 0.001) and degree of differentiation (p = 0.02). Corynebacterium parvum is associated with a decreased survival (p = 0.02). It is concluded that intrapleural Corynebacterium parvum is detrimental to survival.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adenocarcinoma / mortality
  • Adenocarcinoma / surgery
  • Adenocarcinoma / therapy*
  • Adjuvants, Immunologic / adverse effects*
  • Aged
  • Carcinoma, Small Cell / mortality
  • Carcinoma, Small Cell / surgery
  • Carcinoma, Small Cell / therapy*
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / surgery
  • Carcinoma, Squamous Cell / therapy*
  • Combined Modality Therapy
  • Female
  • Fever / etiology
  • Follow-Up Studies
  • Humans
  • Immunotherapy / adverse effects*
  • Lung Neoplasms / mortality
  • Lung Neoplasms / surgery
  • Lung Neoplasms / therapy*
  • Male
  • Middle Aged
  • Prognosis
  • Propionibacterium acnes*
  • Time Factors


  • Adjuvants, Immunologic